Phosphatidylinositol synthesis in mycobacteria

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Phosphatidylinositol (PI) is a crucial lipid component in mycobacteria.
• The synthesis of PI in prokaryotic organisms remains poorly understood.
• Mycobacterial PI synthase exhibits unique characteristics compared to its mammalian counterparts.

Purpose of the Study:

• To investigate the metabolism and synthesis of phosphatidylinositol (PI) in Mycobacterium smegmatis.
• To characterize the enzymatic activity and substrate specificity of mycobacterial PI synthase.
• To evaluate PI synthase as a potential therapeutic target for tuberculosis.

Main Methods:

• Labeling of M. smegmatis cells and subcellular fractions with [3H]inositol.
• Enzymatic assays using PI synthase substrates (CDP-dipalmitoyl-DAG, CDP-NBD-DAG) and varying conditions (CHAPS, metal ions).
• Product identification via Thin Layer Chromatography (TLC), phospholipase C treatment, and ion exchange chromatography.
• Kinetic analysis (K(m) for inositol) and inhibitor studies using inositol analogs and Zn2+.

Main Results:

• PI synthase activity was localized to a cell wall fraction (P60) of M. smegmatis.
• Mycobacterial PI synthase demonstrated strict specificity for endogenous substrates, unlike mammalian and yeast enzymes.
• CHAPS detergent enabled substrate utilization, revealing dose-dependent synthesis of [3H]PI and NBD-PI.
• Kinetic analysis showed a K(m) of 25 microM for inositol, with Mg2+ being a more effective cofactor than Mn2+.
• Structural analogs of myo-inositol and Zn2+ acted as potent inhibitors of mycobacterial PI synthase.

Conclusions:

• Mycobacterial PI synthase exhibits distinct biochemical properties and substrate specificity compared to non-mycobacterial homologs.
• The unique characteristics, including selective inhibitors, position mycobacterial PI synthase as a promising drug target.
• Targeting PI synthase could offer a novel strategy for developing new antituberculosis therapies.